Precigen shares rise 2.11% in after-hours after FDA sets priority review date for PRGN-2012.

Precigen, Inc. surged 2.11% in after-hours trading, following the FDA setting a Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, for the PRGN-2012 biologic license application. The company reported a 51% complete response rate and an 86% reduction in surgical intervention in the Phase 1/2 trial NCT04724980. Precigen focuses on developing next-generation gene and cell therapies, with core areas including immuno-oncology, autoimmune diseases, and infectious diseases.